Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...

Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer-BioNTech and Moderna. People are advised to take whichever vaccine they are offered, as both provide protection against severe illness or death. Getty Images AstraZeneca pulled its Covid ...

They are expected to drop by about 25% in 2025. Sales of Paxlovid and the COVID vaccine are expected to account for 16% of Pfizer's total revenue, estimated to be around $63 billion for 2024 ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

COVID products are still a profit driver for the company. Pfizer is ... is shown in this picture illustration "They still had a pretty significant contribution of both vaccine and Paxlovid in ...